These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 3513532

  • 21. [A new antihypertensive agent used in a clinical setting].
    Wetzels E, Raschig A, Kaiser HJ.
    Med Klin; 1980 Sep 12; 75(19):688-92. PubMed ID: 7001207
    [Abstract] [Full Text] [Related]

  • 22. [Guanfacine versus alpha-methyldopa in benign essential hypertension. An ambulatory group study].
    Rhomberg F, Widler J.
    Schweiz Med Wochenschr; 1981 Dec 12; 111(50):1967-8. PubMed ID: 7036334
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Long-term clinical experience with guanfacine.
    Fetkovská N, Brimichová G, Sebeková K, Dzúrik R.
    Cor Vasa; 1987 Dec 12; 29(4 Suppl 1):23-9. PubMed ID: 3315447
    [Abstract] [Full Text] [Related]

  • 25. The antihypertensive effect of guanfacine compared with methyldopa.
    van der Merwe CJ, Kruger SA.
    S Afr Med J; 1980 Mar 15; 57(11):400-4. PubMed ID: 6105713
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Clinical experience with guanfacine in long-term treatment of hypertension.
    Jerie P.
    Br J Clin Pharmacol; 1980 Mar 15; 10 Suppl 1(Suppl 1):37S-47S. PubMed ID: 6994777
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Effects of guanfacine on growth hormone, prolactin, renin, lipoproteins and glucose in essential hypertension.
    Hauger-Klevene JH, Balossi EC, Scornavacchi JC.
    Am J Cardiol; 1986 Mar 28; 57(9):27E-31E. PubMed ID: 3513527
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Isradipine in essential hypertension: the Belgian General Practitioners' Study.
    De Keyser P, Bouvé J, Clement D, Degraef R, Meurant JP, Rorive G, Van Thillo J.
    Am J Med; 1989 Apr 17; 86(4A):103-9. PubMed ID: 2565687
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Effects of clonidine and guanfacine in essential hypertension.
    Farsang C, Varga K, Vajda L, Alföldi S, Kapocsi J.
    Clin Pharmacol Ther; 1984 Nov 17; 36(5):588-94. PubMed ID: 6386275
    [Abstract] [Full Text] [Related]

  • 36. Blood pressure and prolactin: effects of guanfacine. Three-year follow-up study.
    Hauger-Klevene JH, Pinkas MB, Gerber S.
    Hypertension; 1981 Nov 17; 3(6 Pt 2):II-222-5. PubMed ID: 7028619
    [Abstract] [Full Text] [Related]

  • 37. Clinical dose-response studies with guanfacine (BS 100-141), a new antihypertensive agent.
    MacCarthy P, Isaac P, Frost G, Freeman A, Stokes G.
    Clin Exp Pharmacol Physiol; 1978 Nov 17; 5(2):187-90. PubMed ID: 348364
    [Abstract] [Full Text] [Related]

  • 38. Evaluation of guanfacine and clonidine in essential hypertension: a single-blind crossover study.
    Miach PJ, Louis WJ.
    Med J Aust; 1980 Oct 04; 2(7):395-6. PubMed ID: 7005630
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.